Cardiol Therapeutics Inc Class A Total Liabilities
Cardiol Therapeutics Inc Class A total liabilities. Based on the latest financial reports, Cardiol Therapeutics Inc Class A (CRDL) has total liabilities worth CA$5.74 Million CAD (≈ $4.15 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Cardiol Therapeutics Inc Class A (CRDL) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Cardiol Therapeutics Inc Class A (2017–2025)
Total liabilities of Cardiol Therapeutics Inc Class A from 2017 to 2025. This chart illustrates how Cardiol Therapeutics Inc Class A's total liabilities have evolved over time, based on quarterly financial data.
Cardiol Therapeutics Inc Class A Competitors by Total Liabilities
The table below lists competitors of Cardiol Therapeutics Inc Class A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Oncoclinicas do Brasil
SA:ONCO3
|
Brazil | R$7.02 Billion |
|
Laxmi Goldorna House Ltd
NSE:LGHL
|
India | Rs1.19 Billion |
|
Mpact Limited
JSE:MPT
|
South Africa | ZAC6.42 Billion |
|
Eastech Holding Limited
TW:5225
|
Taiwan | NT$3.66 Billion |
|
CLIO Cosmetics Co.Ltd
KQ:237880
|
Korea | ₩67.89 Billion |
|
Alarko Carrier Sanayi ve Ticaret AS
IS:ALCAR
|
Turkey | TL3.54 Billion |
|
Tharimmune Inc.
NASDAQ:THAR
|
USA | $114.86 Million |
|
Impiana Hotels Bhd
KLSE:7243
|
Malaysia | RM195.30 Million |
Liability Composition Analysis (2017–2025)
This chart breaks down Cardiol Therapeutics Inc Class A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is Cardiol Therapeutics Inc Class A's balance sheet.
Liquidity & Leverage Metrics
Cardiol Therapeutics Inc Class A Total Liabilities Ratios Explained
Cardiol Therapeutics Inc Class A total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.16 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 3.79 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.32 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cardiol Therapeutics Inc Class A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cardiol Therapeutics Inc Class A (2017–2025)
The table below shows the annual total liabilities of Cardiol Therapeutics Inc Class A from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CA$5.74 Million ≈ $4.15 Million |
-19.52% |
| 2024-12-31 | CA$7.14 Million ≈ $5.16 Million |
-15.60% |
| 2023-12-31 | CA$8.45 Million ≈ $6.12 Million |
-13.97% |
| 2022-12-31 | CA$9.83 Million ≈ $7.11 Million |
-15.56% |
| 2021-12-31 | CA$11.64 Million ≈ $8.42 Million |
+343.72% |
| 2020-12-31 | CA$2.62 Million ≈ $1.90 Million |
+215.69% |
| 2019-12-31 | CA$830.83K ≈ $601.01K |
-65.53% |
| 2018-12-31 | CA$2.41 Million ≈ $1.74 Million |
+557.28% |
| 2017-12-31 | CA$366.76K ≈ $265.31K |
-- |
About Cardiol Therapeutics Inc Class A
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for… Read more